This article is more than 5 years old. Information may no longer be current.
Oramed initiates oral insulin study
Click Here to Manage Email Alerts
The first patient has been enrolled in a glucose clamp study undertaken by Oramed Pharmaceuticals, a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, according to a company press release.
The study will be performed at the University of Texas Health Science Center at San Antonio and University Health System’s Texas Diabetes Institute. The glucose clamp is used to quantify insulin absorption to gauge a patient’s insulin sensitivity and ability to metabolize glucose.
Oramed focuses on developing oral delivery methods for drugs currently available only as injections. The company is poised to begin a phase 2b oral insulin trial in the U.S. at more than 30 study sites with approximately 180 patients with type 1 and type 2 diabetes, according to the release.
“We are pleased to have initiated this study and enrolled the first patient,” Nadav Kidron, Oramed CEO, said in the release. “We are additionally excited at the prospects of starting our larger phase 2b trial in the near term. The data from the two trials will allow for a clearer picture of our oral insulin and its pharmacological characteristics as we move forward with our development plan.”